GOTHENBURG, Sweden, July 8, 2026 /PRNewswire/ — SKF will publish its Q2 results for 2026 on 17 July at approximately 07:30 (CEST).

Investors, analysts and media are invited to join an audio webcast, which will be held in English, at 08:30 (CEST).

To join the webcast, please login at least 10 minutes before the start using the below link or phone numbers:
Link to web event: https://www.investis-live.com/skf/6a1d5f4ca4edcf000e53e47f/kcay
Sweden: +46 8 5051 0031
UK / International: +44 203 059 5863

All information regarding the results will be made available on the Group’s IR website: https://www.skf.com/group/investors/financials/quarterly-reports?page=1  

Media: To book interviews with Rickard Gustafson, President and CEO, please contact Carl Bjernstam on carl.bjernstam@skf.com.

Aktiebolaget SKF
(publ)

For further information, please contact:
Press Relations: Carl Bjernstam, +46 31-337 2517; +46 722 201 893; carl.bjernstam@skf.com 
Investor Relations: Sophie Arnius, +46 31-337 8072; +46 705 908072; sophie.arnius@skf.com 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/skf/r/skf-to-publish-q2-report-on-17-july,c4372368

The following files are available for download:

 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Full Truck Alliance Co. Ltd. Announces Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results

GUIYANG, China, March 7, 2024 /PRNewswire/ — Full Truck Alliance Co. Ltd.…

Above Food Congratulates Merger Partner Palm Global Technologies and Subsidiary Palm Promax Investments on Landmark Burkina Faso Stablecoin Agreement and Multi-Trillion-Dollar Gold- and Mineral-Backed Asset Commitment

REGINA, SK, Oct. 24, 2025 /PRNewswire/ — Above Food Ingredients Inc. (NASDAQ:…

Ractigen Therapeutics Presents Positive Phase I Data for RAG-17 in SOD1-ALS at the 2026 AAN Annual Meeting, Demonstrating 81% Reduction in Neurofilament Light Chain

— Single intrathecal dose of SCAD-siRNA therapeutic RAG-17 yields favorable safety profile…